Posted by Michael Wonder on 30 Mar 2021
Samsung Bioepis continues global market expansion with launch of Hadlima in Australia and Canada in partnership with Merck
29 March 2021 - Samsung Bioepis’ adalimumab is now available in three markets: Europe, Canada and Australia.
Samsung Bioepis today announced its expansion of its global footprint to Australia with the launch of Hadlima (adalimumab), a biosimilar referencing Humira (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa and plaque psoriasis.
